Inhibikase Free Cash Flow Operating Cash Flow Ratio from 2010 to 2024
| IKT Stock | USD 3.20 0.01 0.31% |
Free Cash Flow Operating Cash Flow Ratio | First Reported 2010-12-31 | Previous Quarter 1.00078728 | Current Value 1.11 | Quarterly Volatility 0.02525704 |
Check Inhibikase Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Inhibikase Therapeutics' main balance sheet or income statement drivers, such as Interest Expense of 89.9 K, Net Interest Income of 935.8 K or Selling General Administrative of 5.3 M, as well as many indicators such as Price To Sales Ratio of 24.7, Dividend Yield of 0.0 or PTB Ratio of 0.65. Inhibikase financial statements analysis is a perfect complement when working with Inhibikase Therapeutics Valuation or Volatility modules.
Inhibikase | Free Cash Flow Operating Cash Flow Ratio |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Inhibikase Stock Analysis
When running Inhibikase Therapeutics' price analysis, check to measure Inhibikase Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Inhibikase Therapeutics is operating at the current time. Most of Inhibikase Therapeutics' value examination focuses on studying past and present price action to predict the probability of Inhibikase Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Inhibikase Therapeutics' price. Additionally, you may evaluate how the addition of Inhibikase Therapeutics to your portfolios can decrease your overall portfolio volatility.